Beta cell function after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention

D Hofsø, T Jenssen, J Bollerslev, T Ueland, K Godang, M Stumvoll, R Sandbu, J Røislien, J Hjelmesæth, D Hofsø, T Jenssen, J Bollerslev, T Ueland, K Godang, M Stumvoll, R Sandbu, J Røislien, J Hjelmesæth

Abstract

Objective: The effects of various weight loss strategies on pancreatic beta cell function remain unclear. We aimed to compare the effect of intensive lifestyle intervention (ILI) and Roux-en-Y gastric bypass surgery (RYGB) on beta cell function.

Design: One year controlled clinical trial (ClinicalTrials.gov identifier NCT00273104).

Methods: One hundred and nineteen morbidly obese participants without known diabetes from the MOBIL study (mean (s.d.) age 43.6 (10.8) years, body mass index (BMI) 45.5 (5.6) kg/m², 84 women) were allocated to RYGB (n = 64) or ILI (n = 55). The patients underwent repeated oral glucose tolerance tests (OGTTs) and were categorised as having either normal (NGT) or abnormal glucose tolerance (AGT). Twenty-nine normal-weight subjects with NGT (age 42.6 (8.7) years, BMI 22.6 (1.5) kg/m², 19 women) served as controls. OGTT-based indices of beta cell function were calculated.

Results: One year weight reduction was 30% (8) after RYGB and 9% (10) after ILI (P < 0.001). Disposition index (DI) increased in all treatment groups (all P<0.05), although more in the surgery groups (both P < 0.001). Stimulated proinsulin-to-insulin (PI/I) ratio decreased in both surgery groups (both P < 0.001), but to a greater extent in the surgery group with AGT at baseline (P < 0.001). Post surgery, patients with NGT at baseline had higher DI and lower stimulated PI/I ratio than controls (both P < 0.027).

Conclusions: Gastric bypass surgery improved beta cell function to a significantly greater extent than ILI. Supra-physiological insulin secretion and proinsulin processing may indicate excessive beta cell function after gastric bypass surgery.

Figures

Figure 1
Figure 1
Mean glucose, insulin and C-peptide during the OGTT in controls and in morbidly obese subjects at baseline and 1 year after gastric bypass surgery and intensive lifestyle intervention according to glucose tolerance status at baseline. Error bars represent 95% CIs. Independent samples t-tests were used for the comparison of means. *P<0.05, controls versus intervention groups. †P<0.05, surgery versus lifestyle group.
Figure 2
Figure 2
Mean HOMA-S plotted against first phaseest in controls and morbidly obese subjects with normal glucose tolerance (A) and abnormal glucose tolerance (B) before and 1 year after gastric bypass and lifestyle intervention. The curve represents the regression line of the natural logarithm of estimated insulin secretion as a linear function of the natural logarithm of estimated insulin sensitivity for all participants with normal glucose tolerance at baseline. The bar graph (C) represents mean value of the corresponding disposition indices. Error bars represent 95% CIs. *P value for the effect of treatment choice and glucose tolerance status at baseline on change in disposition index, two-way ANOVA. †P<0.05, ††P<0.001, 1 year versus baseline, paired samples t-test. ‡P<0.001, between group (surgery versus lifestyle), changes in disposition index within the same glucose tolerance group, ANCOVA with adjusting for gender, age and BMI at baseline and baseline value. §P<0.001, normal glucose tolerance versus abnormal glucose tolerance within the same intervention group at baseline, independent samples t-test.
Figure 3
Figure 3
Mean stimulated (A) and fasting (B) proinsulin-to-insulin ratios in controls and morbidly obese subjects with normal and abnormal glucose tolerance before and 1 year after gastric bypass and lifestyle intervention. Error bars represent 95% CIs. *P value for the effect of treatment choice and glucose tolerance status at baseline on change in disposition index, two-way ANOVA. ††P<0.001, 1 year versus baseline, paired samples t-test. ‡P<0.001, between groups (surgery versus lifestyle), changes in disposition index within the same glucose tolerance group, ANCOVA with adjusting for gender, age and BMI at baseline and baseline value. §P<0.001, normal glucose tolerance versus abnormal glucose tolerance within the same intervention group at baseline, independent samples t-test.

References

    1. Hofsø D, Jenssen T, Hager H, Røislien J, Hjelmesæth J. Fasting plasma glucose in the screening for type 2 diabetes in morbidly obese subjects. Obesity Surgery. 2010;20:302–307. doi: 10.1007/s11695-009-0022-5.
    1. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333–1346. doi: 10.1016/S0140-6736(05)61032-X.
    1. Golay A, Felber JP, Dusmet M, Gomez F, Curchod B, Jequier E. Effect of weight loss on glucose disposal in obese and obese diabetic patients. International Journal of Obesity. 1985;9:181–191.
    1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393–403. doi: 10.1056/NEJMoa012512.
    1. Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H, Swedish Obese Subjects Study Scientific Group Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. New England Journal of Medicine. 2004;351:2683–2693. doi: 10.1056/NEJMoa035622.
    1. Utzschneider KM, Carr DB, Barsness SM, Kahn SE, Schwartz RS. Diet-induced weight loss is associated with an improvement in beta-cell function in older men. Journal of Clinical Endocrinology and Metabolism. 2004;89:2704–2710. doi: 10.1210/jc.2003-031827.
    1. Villareal DT, Banks MR, Patterson BW, Polonsky KS, Klein S. Weight loss therapy improves pancreatic endocrine function in obese older adults. Obesity. 2008;16:1349–1354. doi: 10.1038/oby.2008.226.
    1. Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, Andres R, Saudek C, Edelstein SL, Arakaki R, Murphy MB, Shamoon H, Diabetes Prevention Program Research Group Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes. 2005;54:2404–2414. doi: 10.2337/diabetes.54.8.2404.
    1. Carr DB, Utzschneider KM, Boyko EJ, Asberry PJ, Hull RL, Kodama K, Callahan HS, Matthys CC, Leonetti DL, Schwartz RS, Kahn SE, Fujimoto WY. A reduced-fat diet and aerobic exercise in Japanese Americans with impaired glucose tolerance decreases intra-abdominal fat and improves insulin sensitivity but not beta-cell function. Diabetes. 2005;54:340–347. doi: 10.2337/diabetes.54.2.340.
    1. Morinigo R, Lacy AM, Casamitjana R, Delgado S, Gomis R, Vidal J. GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. Obesity Surgery. 2006;16:1594–1601. doi: 10.1381/096089206779319338.
    1. Salinari S, Bertuzzi A, Asnaghi S, Guidone C, Manco M, Mingrone G. First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery. Diabetes Care. 2009;32:375–380. doi: 10.2337/dc08-1314.
    1. Guldstrand M, Ahren B, Adamson U. Improved beta-cell function after standardized weight reduction in severely obese subjects. American Journal of Physiology. Endocrinology and Metabolism. 2003;284:E557–E565. doi: 10.1152/ajpendo.00325.2002.
    1. Goldfine AB, Mun EC, Devine E, Bernier R, Baz-Hecht M, Jones DB, Schneider BE, Holst JJ, Patti ME. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. Journal of Clinical Endocrinology and Metabolism. 2007;92:4678–4685. doi: 10.1210/jc.2007-0918.
    1. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. New England Journal of Medicine. 2005;353:249–254. doi: 10.1056/NEJMoa043690.
    1. Hofsø D, Nordstrand N, Johnson LK, Karlsen TI, Hager H, Jenssen T, Bollerslev J, Godang K, Sandbu R, Røislien J, Hjelmesæth J. Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. European Journal of Endocrinology. 2010;163:735–745. doi: 10.1530/EJE-10-0514.
    1. Hofsø D, Ueland T, Hager H, Jenssen T, Bollerslev J, Godang K, Aukrust P, Røislien J, Hjelmesæth J. Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose. European Journal of Endocrinology. 2009;161:451–458. doi: 10.1530/EJE-09-0421.
    1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine. 1998;15:539–553. doi: 10.1002/(SICI)1096-9136(199807)15:7%3C539::AID-DIA668%;2-S.
    1. Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419. doi: 10.1007/BF00280883.
    1. Belfiore F, Iannello S, Volpicelli G. Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. Molecular Genetics and Metabolism. 1998;63:134–141. doi: 10.1006/mgme.1997.2658.
    1. Stumvoll M, Van HT, Fritsche A, Gerich J. Oral glucose tolerance test indexes for insulin sensitivity and secretion based on various availabilities of sampling times. Diabetes Care. 2001;24:796–797. doi: 10.2337/diacare.24.4.796.
    1. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 1993;42:1663–1672. doi: 10.2337/diabetes.42.11.1663.
    1. Larsson H, Ahren B. Relative hyperproinsulinemia as a sign of islet dysfunction in women with impaired glucose tolerance. Journal of Clinical Endocrinology and Metabolism. 1999;84:2068–2074. doi: 10.1210/jc.84.6.2068.
    1. Fritsche A, Madaus A, Stefan N, Tschritter O, Maerker E, Teigeler A, Haring H, Stumvoll M. Relationships among age, proinsulin conversion, and beta-cell function in nondiabetic humans. Diabetes. 2002;51:S234–S239. doi: 10.2337/diabetes.51.2007.S234.
    1. Weyer C, Hanson K, Bogardus C, Pratley RE. Long-term changes in insulin action and insulin secretion associated with gain, loss, regain and maintenance of body weight. Diabetologia. 2000;43:36–46. doi: 10.1007/s001250050005.
    1. Laferrere B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A, Kovack B, Bawa B, Koshy N, Lee H, Yapp K, Olivan B. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 2008;93:2479–2485. doi: 10.1210/jc.2007-2851.
    1. Swarbrick MM, Stanhope KL, Austrheim-Smith IT, Van L, Ali MR, Wolfe BM, Havel PJ. Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. Diabetologia. 2008;51:1901–1911. doi: 10.1007/s00125-008-1118-5.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever